{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:32:49Z","timestamp":1707525169238},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,13]]},"DOI":"10.7759\/cureus.40368","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T14:49:44Z","timestamp":1686667784000},"source":"Crossref","is-referenced-by-count":1,"title":["Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate"],"prefix":"10.7759","author":[{"given":"Jaskaran","family":"Batra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anvitha R","family":"Ankireddypalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok Kumar","family":"Kanugula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swathi","family":"Gorle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasleen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4065\/77.5.453","article-title":"Secondary causes of osteoporosis","volume":"77","author":"Fitzpatrick LA","year":"2002","unstructured":"Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002, 77:453-68. 10.4065\/77.5.453","journal-title":"Mayo Clin Proc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4158\/EP12059.RA","article-title":"Secondary causes of osteoporosis","volume":"19","author":"Hudec SM","year":"2013","unstructured":"Hudec SM, Camacho PM. Secondary causes of osteoporosis. Endocr Pract. 2013, 19:120-8. 10.4158\/EP12059.RA","journal-title":"Endocr Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab028","article-title":"Secondary osteoporosis","volume":"43","author":"Ebeling PR","year":"2022","unstructured":"Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary osteoporosis. Endocr Rev. 2022, 43:240-313. 10.1210\/endrev\/bnab028","journal-title":"Endocr Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2478","article-title":"Life expectancy in patients treated for osteoporosis: observational cohort study using national Danish prescription data","volume":"30","author":"Abrahamsen B","year":"2015","unstructured":"Abrahamsen B, Osmond C, Cooper C. Life expectancy in patients treated for osteoporosis: observational cohort study using national Danish prescription data. J Bone Miner Res. 2015, 30:1553-9. 10.1002\/jbmr.2478","journal-title":"J Bone Miner Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc D","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009, 301:513-21. 10.1001\/jama.2009.50","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour E","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020, 95:691-709. 10.1002\/ajh.25792","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian H","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, et al.. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002, 346:645-52. 10.1056\/NEJMoa011573","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17989","article-title":"The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018","volume":"196","author":"Maas CC","year":"2022","unstructured":"Maas CC, van Klaveren D, Ector GI, et al.. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018. Br J Haematol. 2022, 196:1219-24. 10.1111\/bjh.17989","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang X","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012, 118:3123-7. 10.1002\/cncr.26679","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen P","year":"2021","unstructured":"Cohen P, Cross D, J\u00e4nne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021, 20:551-69. 10.1038\/s41573-021-00195-4","journal-title":"Nat Rev Drug Discov"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvv112","article-title":"The role of osteoclast differentiation and function in skeletal homeostasis","volume":"159","author":"Ikeda K","year":"2016","unstructured":"Ikeda K, Takeshita S. The role of osteoclast differentiation and function in skeletal homeostasis. J Biochem. 2016, 159:1-8. 10.1093\/jb\/mvv112","journal-title":"J Biochem"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-12-0400","article-title":"Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies","volume":"21","author":"Alem\u00e1n JO","year":"2014","unstructured":"Alem\u00e1n JO, Farooki A, Girotra M. Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocr Relat Cancer. 2014, 21:R247-59. 10.1530\/ERC-12-0400","journal-title":"Endocr Relat Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman E","year":"2006","unstructured":"Berman E, Nicolaides M, Maki RG, et al.. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006, 354:2006-13. 10.1056\/NEJMoa051140","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2324","article-title":"Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib","volume":"94","author":"O'Sullivan S","year":"2009","unstructured":"O'Sullivan S, Horne A, Wattie D, et al.. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab. 2009, 94:1131-6. 10.1210\/jc.2008-2324","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.02.005","article-title":"Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors","volume":"37","author":"Berman E","year":"2013","unstructured":"Berman E, Girotra M, Cheng C, et al.. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res. 2013, 37:790-4. 10.1016\/j.leukres.2013.02.005","journal-title":"Leuk Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2426","article-title":"Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects","volume":"98","author":"Vandyke K","year":"2013","unstructured":"Vandyke K, Fitter S, Drew J, et al.. Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. J Clin Endocrinol Metab. 2013, 98:67-76. 10.1210\/jc.2012-2426","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/159939-osteoporosis-in-a-60-year-old-male-with-a-history-of-chronic-myeloid-leukemia-treated-with-imatinib-mesylate","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:28Z","timestamp":1707508948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/159939-osteoporosis-in-a-60-year-old-male-with-a-history-of-chronic-myeloid-leukemia-treated-with-imatinib-mesylate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.40368","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,13]]}}}